Journal article
The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review
Abstract
Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and harms of denosumab compared with no denosumab in terms of (1) facilitation of surgery (operative time, blood loss), (2) disease recurrence, (3) pain control, (4) disease stability, and (5) adverse …
Authors
Gupta A; Durocher-Allen L; Popovic S; Tozer R; Yao X; Ghert M
Journal
Current Oncology, Vol. 28, No. 2, pp. 1302–1313
Publisher
MDPI
DOI
10.3390/curroncol28020124
ISSN
1198-0052